Background: Whenever suitable template structures are not available, usage of fragment-based protein structure prediction becomes the only practical alternative as pure ab initio techniques require massive computational resources even for very small proteins. However, inaccuracy of their energy functions and their stochastic nature imposes generation of a large number of decoys to explore adequately the solution space, limiting their usage to small proteins. Taking advantage of the uneven complexity of the sequence-structure relationship of short fragments, we adjusted the fragment insertion process by customising the number of available fragment templates according to the expected complexity of the predicted local secondary structure. Whereas the number of fragments is kept to its default value for coil regions, important and dramatic reductions are proposed for beta sheet and alpha helical regions, respectively.
Results: The evaluation of our fragment selection approach was conducted using an enhanced version of the popular Rosetta fragment-based protein structure prediction tool. It was modified so that the number of fragment candidates used in Rosetta could be adjusted based on the local secondary structure. Compared to Rosetta's standard predictions, our strategy delivered improved first models, + 24% and + 6% in terms of GDT, when using 2000 and 20,000 decoys, respectively, while reducing significantly the number of fragment candidates. Furthermore, our enhanced version of Rosetta is able to deliver with 2000 decoys a performance equivalent to that produced by standard Rosetta while using 20,000 decoys. We hypothesise that, as the fragment insertion process focuses on the most challenging regions, such as coils, fewer decoys are needed to explore satisfactorily conformation spaces.
Conclusions: Taking advantage of the high accuracy of sequence-based secondary structure predictions, we showed the value of that information to customise the number of candidates used during the fragment insertion process of fragment-based protein structure prediction. Experimentations conducted using standard Rosetta showed that, when using the recommended number of decoys, i.e. 20,000, our strategy produces better results. Alternatively, similar results can be achieved using only 2000 decoys. Consequently, we recommend the adoption of this strategy to either improve significantly model quality or reduce processing times by a factor 10.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195757 | PMC |
http://dx.doi.org/10.1186/s12859-020-3491-0 | DOI Listing |
Bioorg Chem
January 2025
Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal, Academy of Higher Education, Manipal, Karnataka 576104, India.
Fragment-Based Drug Discovery (FBDD) has revolutionized drug discovery by overcoming the challenges of traditional methods like combinatorial chemistry and high-throughput screening (HTS). Leveraging small, low-molecular-weight fragments, FBDD achieves higher hit rates, reduced screening costs, and faster development timelines for clinically relevant drug candidates. This review explores FBDD's core principles, innovative methodologies, and its success in targeting diverse protein classes, including previously "undruggable" targets.
View Article and Find Full Text PDFInt J Mol Sci
January 2025
Key Laboratory of Chemical Biology (Ministry of Education), Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, Jinan 250012, China.
With the aim of developing novel anti-SARS-CoV-2 drugs to address the ongoing evolution and emergence of drug-resistant strains, the reported SARS-CoV-2 M inhibitor was selected as a lead to find novel, highly potent, and broad-spectrum inhibitors. Using a fragment-based multilevel virtual screening strategy, 15 hit compounds were identified and subsequently synthesized. Among them, (IC = 1.
View Article and Find Full Text PDFInt J Mol Sci
January 2025
Department of Applied Biotechnology, Faculty of Chemistry, Warsaw University of Technology, 00-661 Warsaw, Poland.
This study evaluates the performance of various structure prediction tools and molecular docking platforms for therapeutic peptides targeting coronary artery disease (CAD). Structure prediction tools, including AlphaFold 3, I-TASSER 5.1, and PEP-FOLD 4, were employed to generate accurate peptide conformations.
View Article and Find Full Text PDFDrug Res (Stuttg)
January 2025
Department of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang China.
Fragment based novel drug identification and its validation through use of molecular dynamics and simulations.Comparing primary microcephaly genes with glioblastoma expression profiles reveals potential oncogenes, with proteins that support growth and survival in neural stem/progenitor cells likely retaining critical roles in glioblastoma. Identifying such proteins in familial and congenital microcephalic disorders offers promising targets for brain tumor therapy.
View Article and Find Full Text PDFACS Chem Biol
January 2025
Department of Chemistry, University of Florida, Gainesville Florida 32611, United States.
Small molecules are essential for investigating the pharmacology of membrane proteins and remain the most common approach for therapeutically targeting them. However, most experimental small molecule screening methods require ligands containing radiolabels or fluorescent labels and often involve isolating proteins from their cellular environment. Additionally, most conventional screening methods are suited for identifying compounds with moderate to higher affinities ( < 1 μM) and are less effective at detecting lower affinity compounds, such as weakly binding molecular fragments.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!